Patent ID: 7226601

Claim:
A method for the treatment of a disease condition in a mammal, which condition means the presence of specific cells that are associated with the condition by the expression of a disease specific cell surface structure, wherein one administers to the mammal a therapeutically effective amount of covalent conjugate that is able to activate T lymphocytes to lyse cells that carry the disease specific cell surface structure and comprises: a. a biospecific affinity counterpart that is capable of binding to said surface structure, and b. a peptide that i. contains an amino acid sequence that is derived from staphylococcal enterotoxin A, wherein said peptide has the ability to bind to a Vβ of a T cell receptor, and ii. has been mutated in that amino acid substitution D227A has been made in staphylococcal enterotoxin A to show a modified ability to bind to MHC class II antigens.